Litcius/Paper detail

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai, Masayuki Hino, Toshio Heike, Masaya Okada, Hideo Tanaka, Motohiro Shindo, Takashi Kumagai, Takayuki Ikezoe, Nobuhiko Uoshima, Tsutomu Sato, Reiko Watanabe, Shugo Kowata, Masaya Hayakawa, Takaaki Hosoki, Kazuhiko Ikeda, Tsutomu Kobayashi, Yasutaka Kakinoki, Tetsuo Nishimoto, Naoki Takezako, Hirohiko Shibayama, Akifumi Takaori‐Kondo, Hirohisa Nakamae, Atsushi Kawaguchi, Hiroshi Ureshino, Junichi Sakamoto, Yoji Ishida

2020The Lancet Haematology101 citationsDOI

Topics & Concepts

DasatinibMedicineDiscontinuationInternal medicineClinical trialOncologySurgeryImatinibMyeloid leukemiaChronic Myeloid Leukemia TreatmentsLung Cancer Treatments and MutationsAcute Myeloid Leukemia Research
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial | Litcius